{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:29:00Z","timestamp":1793860140279,"version":"4.6.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11619-x","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:07:40Z","timestamp":1782630460000},"page":"9723-9744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a double-pharmacophore workflow for screening subtype-selective M3 muscarinic acetylcholine receptor antagonists"],"prefix":"10.1007","volume":"30","author":[{"given":"Sirat Kaur","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam Sundar","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Yadava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant","family":"Sindhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4946-5311","authenticated-orcid":false,"given":"Badri N.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"11619_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","volume":"63","author":"R Fredriksson","year":"2003","unstructured":"Fredriksson R, Lagerstr\u00f6m MC, Lundin L-G, Schi\u00f6th HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256\u20131272. https:\/\/doi.org\/10.1124\/mol.63.6.1256","journal-title":"Mol Pharmacol"},{"key":"11619_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nature17188","volume":"531","author":"DM Thal","year":"2016","unstructured":"Thal DM, Sun B, Feng D et al (2016) Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531:335\u2013340. https:\/\/doi.org\/10.1038\/nature17188","journal-title":"Nature"},{"key":"11619_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10753","volume":"482","author":"K Haga","year":"2012","unstructured":"Haga K, Kruse AC, Asada H et al (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482:547\u2013551. https:\/\/doi.org\/10.1038\/nature10753","journal-title":"Nature"},{"key":"11619_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature10867","volume":"482","author":"AC Kruse","year":"2012","unstructured":"Kruse AC, Hu J, Pan AC et al (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482:552\u2013556. https:\/\/doi.org\/10.1038\/nature10867","journal-title":"Nature"},{"key":"11619_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrd2379","volume":"6","author":"J Wess","year":"2007","unstructured":"Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721\u2013733. https:\/\/doi.org\/10.1038\/nrd2379","journal-title":"Nat Rev Drug Discov"},{"key":"11619_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","volume":"50","author":"MP Caulfield","year":"1998","unstructured":"Caulfield MP, Birdsall NJ (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279\u2013290","journal-title":"Pharmacol Rev"},{"key":"11619_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-23274-9","volume-title":"Muscarinic receptors","author":"AD Fryer","year":"2012","unstructured":"Fryer AD, Christopoulos A, Nathanson NM (2012) Muscarinic receptors. Springer Berlin Heidelberg, Berlin, Heidelberg"},{"key":"11619_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/409580","volume":"2012","author":"G Karakiulakis","year":"2012","unstructured":"Karakiulakis G, Roth M (2012) Muscarinic receptors and their antagonists in COPD: anti-inflammatory and antiremodeling effects. Mediat Inflamm 2012:1\u20139. https:\/\/doi.org\/10.1155\/2012\/409580","journal-title":"Mediators Inflamm"},{"key":"11619_CR9","doi-asserted-by":"publisher","first-page":"107956","DOI":"10.1016\/j.rmed.2025.107956","volume":"238","author":"L Calzetta","year":"2025","unstructured":"Calzetta L, Pistocchini E, Laitano R et al (2025) Efficacy and safety of long-acting muscarinic antagonists in COPD: a meta-analysis and meta-regression with a focus on aging. Respir Med 238:107956. https:\/\/doi.org\/10.1016\/j.rmed.2025.107956","journal-title":"Respir Med"},{"key":"11619_CR10","doi-asserted-by":"publisher","first-page":"G215","DOI":"10.1152\/ajpgi.00072.2010","volume":"299","author":"AE Bharucha","year":"2010","unstructured":"Bharucha AE, Ravi K, Zinsmeister AR (2010) Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol 299:G215\u2013G219. https:\/\/doi.org\/10.1152\/ajpgi.00072.2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"11619_CR11","doi-asserted-by":"crossref","unstructured":"Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148","DOI":"10.1038\/sj.bjp.0706780"},{"key":"11619_CR12","doi-asserted-by":"publisher","unstructured":"Mitchelson F (2012) Muscarinic Receptor Agonists and Antagonists: Effects on Ocular Function. In: Fryer, A., Christopoulos, A., Nathanson, N. (eds) Muscarinic Receptors. Handbook of Experimental Pharmacology, vol 208. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-23274-9_12","DOI":"10.1007\/978-3-642-23274-9_12"},{"key":"11619_CR13","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.2147\/OPTH.S388982","volume":"16","author":"H Contreras-Salinas","year":"2022","unstructured":"Contreras-Salinas H, Orozco-Ceja V, Romero-L\u00f3pez MS et al (2022) Ocular cyclopentolate: a mini review concerning its benefits and risks. Clin Ophthalmol 16:3753\u20133762. https:\/\/doi.org\/10.2147\/OPTH.S388982","journal-title":"Clin Ophthalmol"},{"key":"11619_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s40123-024-00951-w","volume":"13","author":"LS Eppenberger","year":"2024","unstructured":"Eppenberger LS, Grzybowski A, Schmetterer L, Ang M (2024) Myopia control: Are we ready for an evidence based approach? Ophthalmol Ther 13:1453\u20131477. https:\/\/doi.org\/10.1007\/s40123-024-00951-w","journal-title":"Ophthalmol Ther"},{"key":"11619_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1113\/jphysiol.2004.064626","volume":"558","author":"T Nakamura","year":"2004","unstructured":"Nakamura T, Matsui M, Uchida K et al (2004) M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J Physiol 558:561\u2013575. https:\/\/doi.org\/10.1113\/jphysiol.2004.064626","journal-title":"J Physiol"},{"key":"11619_CR16","doi-asserted-by":"publisher","unstructured":"Yamamura Y, Nonaka M (2019) Sialorrhea successfully treated by the combined use of selective M1 and M3 muscarinic acetylcholine receptor antagonists. J Nippon Med Sch 86. https:\/\/doi.org\/10.1272\/jnms.JNMS.2019_86-207","DOI":"10.1272\/jnms.JNMS.2019_86-207"},{"key":"11619_CR17","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1164\/rccm.201406-1150CI","volume":"190","author":"EJ Hulse","year":"2014","unstructured":"Hulse EJ, Davies JOJ, Simpson AJ et al (2014) Respiratory complications of organophosphorus nerve agent and insecticide poisoning. Implications for respiratory and critical care. Am J Respir Crit Care Med 190:1342\u20131354. https:\/\/doi.org\/10.1164\/rccm.201406-1150CI","journal-title":"Am J Respir Crit Care Med"},{"key":"11619_CR18","unstructured":"Robb EL, Regina AC, Baker MB (2023) Organophosphate toxicity. Stat Pearls"},{"key":"11619_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.lfs.2003.09.023","volume":"74","author":"FJ Ehlert","year":"2003","unstructured":"Ehlert FJ (2003) Contractile role of M2 and M3 muscarinic receptors in gastrointestinal, airway and urinary bladder smooth muscle. Life Sci 74:355\u2013366. https:\/\/doi.org\/10.1016\/j.lfs.2003.09.023","journal-title":"Life Sci"},{"key":"11619_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1006\/phrs.2001.0835","volume":"44","author":"S Dhein","year":"2001","unstructured":"Dhein S, Van Koppen CJ, Brodde OE (2001) Muscarinic receptors in the mammalian heart. Pharmacol Res 44:161\u2013182. https:\/\/doi.org\/10.1006\/phrs.2001.0835","journal-title":"Pharmacol Res"},{"key":"11619_CR21","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.bjp.0705338","volume":"139","author":"RD Harvey","year":"2003","unstructured":"Harvey RD, Belevych AE (2003) Muscarinic regulation of cardiac ion channels. Br J Pharmacol 139:1074\u20131084. https:\/\/doi.org\/10.1038\/sj.bjp.0705338","journal-title":"Br J Pharmacol"},{"key":"11619_CR22","doi-asserted-by":"publisher","unstructured":"Myslivecek J (2022) Multitargeting nature of muscarinic orthosteric agonists and antagonists. Front Physiol 13. https:\/\/doi.org\/10.3389\/fphys.2022.974160","DOI":"10.3389\/fphys.2022.974160"},{"key":"11619_CR23","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0024-3205(97)00047-7","volume":"60","author":"VA Alabaster","year":"1997","unstructured":"Alabaster VA (1997) Discovery & development of selective M3 antagonists for clinical use. Life Sci 60:1053\u20131060. https:\/\/doi.org\/10.1016\/S0024-3205(97)00047-7","journal-title":"Life Sci"},{"key":"11619_CR24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1464-410X.2005.05454.x","volume":"95","author":"C Chapple","year":"2005","unstructured":"Chapple C, Steers W, Norton P et al (2005) A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 95:993\u20131001. https:\/\/doi.org\/10.1111\/j.1464-410X.2005.05454.x","journal-title":"BJU Int"},{"key":"11619_CR25","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1183\/09031936.06.00126005","volume":"28","author":"S Lu","year":"2006","unstructured":"Lu S, Parekh DD, Kuznetsova O et al (2006) An oral selective M3 cholinergic receptor antagonist in COPD. Eur Respir J 28:772\u2013780. https:\/\/doi.org\/10.1183\/09031936.06.00126005","journal-title":"Eur Respir J"},{"key":"11619_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ucl.2006.06.008","volume":"33","author":"KJ Kreder","year":"2006","unstructured":"Kreder KJ (2006) Solifenacin. Urol Clin North Am 33:483\u2013490. https:\/\/doi.org\/10.1016\/j.ucl.2006.06.008","journal-title":"Urol Clin North Am"},{"key":"11619_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003088-200948050-00001","volume":"48","author":"O Doroshyenko","year":"2009","unstructured":"Doroshyenko O, Fuhr U (2009) Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet 48:281\u2013302. https:\/\/doi.org\/10.2165\/00003088-200948050-00001","journal-title":"Clin Pharmacokinet"},{"key":"11619_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/PL00007103","volume":"19","author":"KE Andersson","year":"2001","unstructured":"Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urol 19:319\u2013323. https:\/\/doi.org\/10.1007\/PL00007103","journal-title":"World J Urol"},{"key":"11619_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0014-2999(97)89661-6","volume":"327","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant L, Andersson KE, Gillberg PG et al (1997) Tolterodine\u2014a new bladder-selective antimuscarinic agent. Eur J Pharmacol 327:195\u2013207. https:\/\/doi.org\/10.1016\/s0014-2999(97)89661-6","journal-title":"Eur J Pharmacol"},{"key":"11619_CR30","doi-asserted-by":"publisher","unstructured":"Zinner N, Gittelman M, Harris R et al (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171:2311\u20132315. https:\/\/doi.org\/10.1097\/01.ju.0000127742.73136.0c","DOI":"10.1097\/01.ju.0000127742.73136.0c"},{"key":"11619_CR31","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2165\/00003495-200464210-00005","volume":"64","author":"ES Rovner","year":"2004","unstructured":"Rovner ES (2004) Trospium chloride in the management of overactive bladder. Drugs 64:2433\u20132446. https:\/\/doi.org\/10.2165\/00003495-200464210-00005","journal-title":"Drugs"},{"key":"11619_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1055\/s-0031-1296589","volume":"57","author":"F Kobayashi","year":"2011","unstructured":"Kobayashi F, Yageta Y, Segawa M, Matsuzawa S (2011) Effects of imidafenacin (KRP-197\/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. Arzneimittelforschung 57:92\u2013100. https:\/\/doi.org\/10.1055\/s-0031-1296589","journal-title":"Arzneimittelforschung"},{"key":"11619_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00004836-198106000-00009","volume":"3","author":"JG Page","year":"1981","unstructured":"Page JG, Dirnberger GM (1981) Treatment of the irritable bowel syndrome with bentyl\u00ae (dicyclomine hydrochloride). J Clin Gastroenterol 3:153\u2013156. https:\/\/doi.org\/10.1097\/00004836-198106000-00009","journal-title":"J Clin Gastroenterol"},{"key":"11619_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1046\/j.1365-2036.1997.00189.x","volume":"11","author":"LA Houghton","year":"1997","unstructured":"Houghton LA, Rogers J, Whorwell PJ et al (1997) Zamifenacin (UK-76,\u2003654), a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 11:561\u2013568. https:\/\/doi.org\/10.1046\/j.1365-2036.1997.00189.x","journal-title":"Aliment Pharmacol Ther"},{"key":"11619_CR35","first-page":"467","volume":"5","author":"C Scarpignato","year":"1985","unstructured":"Scarpignato C, Bianchi Porro G (1985) Cimetropium bromide, a new antispasmodic compound: pharmacology and therapeutic perspectives. Int J Clin Pharmacol Res 5:467\u2013477","journal-title":"Int J Clin Pharmacol Res"},{"key":"11619_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/030006059902700501","volume":"27","author":"S Evangelista","year":"1999","unstructured":"Evangelista S (1999) Otilonium bromide: a selective spasmolytic for the gastrointestinal tract. J Int Med Res 27:207\u2013222. https:\/\/doi.org\/10.1177\/030006059902700501","journal-title":"J Int Med Res"},{"key":"11619_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1124\/jpet.112.202051","volume":"345","author":"M Salmon","year":"2013","unstructured":"Salmon M, Luttmann MA, Foley JJ et al (2013) Pharmacological characterization of GSK573719 (Umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 345:260\u2013270. https:\/\/doi.org\/10.1124\/jpet.112.202051","journal-title":"J Pharmacol Exp Ther"},{"key":"11619_CR38","doi-asserted-by":"publisher","unstructured":"Hegde SS, Pulido-Rios MT, Luttmann MA et al (2018) Pharmacological properties of revefenacin (TD \u20104208), a novel, nebulized long\u2010acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect 6. https:\/\/doi.org\/10.1002\/prp2.400","DOI":"10.1002\/prp2.400"},{"key":"11619_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/COPD.S3530","volume":"3","author":"Y Oba","year":"2008","unstructured":"Oba Y, Zaza T (2008) Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis Volume 3:575\u2013584. https:\/\/doi.org\/10.2147\/COPD.S3530","journal-title":"Int J Chron Obstruct Pulmon Dis Volume"},{"key":"11619_CR40","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4103\/lungindia.lungindia_92_22","volume":"39","author":"S Salvi","year":"2022","unstructured":"Salvi S, Kumar A, Agrawal S et al (2022) Efficacy and safety of glycopyrronium\/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease. Lung India 39:408\u2013416. https:\/\/doi.org\/10.4103\/lungindia.lungindia_92_22","journal-title":"Lung India"},{"key":"11619_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0140-6736(07)61202-1","volume":"371","author":"M Eddleston","year":"2008","unstructured":"Eddleston M, Buckley NA, Eyer P, Dawson AH (2008) Management of acute organophosphorus pesticide poisoning. Lancet 371:597\u2013607. https:\/\/doi.org\/10.1016\/S0140-6736(07)61202-1","journal-title":"Lancet"},{"key":"11619_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM et al (2019) Low-concentration atropine for myopia progression (LAMP) study. Ophthalmology 126:113\u2013124. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029","journal-title":"Ophthalmology"},{"key":"11619_CR43","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/med.20158","volume":"29","author":"I Peretto","year":"2009","unstructured":"Peretto I, Petrillo P, Imbimbo BP (2009) Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Med Res Rev 29:867\u2013902. https:\/\/doi.org\/10.1002\/med.20158","journal-title":"Med Res Rev"},{"key":"11619_CR44","unstructured":"2024 GOLD Report\u2014Global Initiative for Chronic Obstructive Lung Disease\u2014GOLD. https:\/\/goldcopd.org\/2024-gold-report\/. Accessed 26 Feb 2026"},{"key":"11619_CR45","first-page":"3543","volume":"65","author":"MJ Kim","year":"2024","unstructured":"Kim MJ, Ibrahim M, Jablonski MM (2024) Shared binding modes of M3 muscarinic agonists and antagonists may incentivize development of novel IOP-reducing drugs. Invest Ophthalmol Vis Sci 65:3543\u20133543","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"11619_CR46","unstructured":"Muscarinic Antagonists\u2014StatPearls\u2014NCBI Bookshelf https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557541\/. Accessed 26 Feb 2026"},{"key":"11619_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2014.02.006","volume":"16","author":"AC Kruse","year":"2014","unstructured":"Kruse AC, Hu J, Kobilka BK, Wess J (2014) Muscarinic acetylcholine receptor x-ray structures: potential implications for drug development. Curr Opin Pharmacol 16:24\u201330. https:\/\/doi.org\/10.1016\/j.coph.2014.02.006","journal-title":"Curr Opin Pharmacol"},{"key":"11619_CR48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/ph18030369","volume":"18","author":"H Tsimpili","year":"2025","unstructured":"Tsimpili H, Zoidis G (2025) A new era of muscarinic acetylcholine receptor modulators in neurological diseases, cancer and drug abuse. Pharmaceuticals 18:369. https:\/\/doi.org\/10.3390\/ph18030369","journal-title":"Pharmaceuticals"},{"key":"11619_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11208-4","author":"SK Gill","year":"2025","unstructured":"Gill SK, Kumari S, Biswal BK, Acharya BN (2025) From pharmacophore predictions to pharmaceutical possibilities: an integrated approach to screen M3 selective muscarinic receptor antagonist. Mol Divers. https:\/\/doi.org\/10.1007\/s11030-025-11208-4","journal-title":"Mol Divers"},{"key":"11619_CR50","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256","journal-title":"J Comput Chem"},{"key":"11619_CR51","unstructured":"Accelrys inc (2007) Discovery Studio"},{"key":"11619_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-1-4939-9752-7_13","volume-title":"Molecular docking simulations with ArgusLab BT\u2014docking screens for drug discovery","author":"G Bitencourt-Ferreira","year":"2019","unstructured":"Bitencourt-Ferreira G, de Azevedo WF (2019) Molecular docking simulations with ArgusLab BT\u2014docking screens for drug discovery. In: de Azevedo Jr WF (ed) Springer New York, New York, NY, pp 203\u2013220"},{"key":"11619_CR53","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1021\/ja00299a024","volume":"107","author":"MJS Dewar","year":"2002","unstructured":"Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP (2002) Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 107:3902\u20133909. https:\/\/doi.org\/10.1021\/ja00299a024","journal-title":"J Am Chem Soc"},{"key":"11619_CR54","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC et al (2004) UCSF Chimera\u2014a visualization system for exploratory research and analysis. J Comput Chem 25:1605\u20131612. https:\/\/doi.org\/10.1002\/jcc.20084","journal-title":"J Comput Chem"},{"key":"11619_CR55","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.1021\/acs.jpcb.4c04901","volume":"128","author":"JA Lemkul","year":"2024","unstructured":"Lemkul JA (2024) Introductory tutorials for simulating protein dynamics with GROMACS. J Phys Chem B 128:9418\u20139435. https:\/\/doi.org\/10.1021\/acs.jpcb.4c04901","journal-title":"J Phys Chem B"},{"key":"11619_CR56","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1021\/jm061159a","volume":"50","author":"I Peretto","year":"2007","unstructured":"Peretto I, Forlani R, Fossati C et al (2007) Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1). J Med Chem 50:1571\u20131583. https:\/\/doi.org\/10.1021\/jm061159a","journal-title":"J Med Chem"},{"key":"11619_CR57","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1021\/jm061160+","volume":"50","author":"I Peretto","year":"2007","unstructured":"Peretto I, Fossati C, Giardina M GA, et al (2007) Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 2). J Med Chem 50:1693\u20131697. https:\/\/doi.org\/10.1021\/jm061160+","journal-title":"J Med Chem"},{"key":"11619_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1813988115","author":"H Liu","year":"2018","unstructured":"Liu H, Hofmann J, Fish I et al (2018) Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.1813988115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11619_CR59","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1021\/jm9705115","volume":"41","author":"X-F Pei","year":"1998","unstructured":"Pei X-F, Gupta TH, Badio B et al (1998) 6\u03b2-acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem 41:2047\u20132055. https:\/\/doi.org\/10.1021\/jm9705115","journal-title":"J Med Chem"},{"key":"11619_CR60","doi-asserted-by":"publisher","unstructured":"Mandelli GR, Maiorana S, Terni P et al (2001) Synthesis of new cardioselective M2 muscarinic receptor antagonists. ChemInform. https:\/\/doi.org\/10.1002\/chin.200116164","DOI":"10.1002\/chin.200116164"},{"key":"11619_CR61","doi-asserted-by":"publisher","first-page":"127632","DOI":"10.1016\/j.bmcl.2020.127632","volume":"30","author":"M Li","year":"2020","unstructured":"Li M, Huang C, Wu X et al (2020) The optimization of a novel selective antagonist for human M2 muscarinic acetylcholine receptor. Bioorg Med Chem Lett 30:127632. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127632","journal-title":"Bioorg Med Chem Lett"},{"key":"11619_CR62","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1021\/jm801601v","volume":"52","author":"DI Lain\u00e9","year":"2009","unstructured":"Lain\u00e9 DI, McCleland B, Thomas S et al (2009) Discovery of novel 1-azoniabicyclo [2.2.2] octane muscarinic acetylcholine receptor antagonists. J Med Chem 52:2493\u20132505. https:\/\/doi.org\/10.1021\/jm801601v","journal-title":"J Med Chem"},{"key":"11619_CR63","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1021\/jm801503n","volume":"52","author":"SK De","year":"2009","unstructured":"De SK, Stebbins JL, Chen L-H et al (2009) Design, Synthesis, and structure\u2013activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem 52:1943\u20131952. https:\/\/doi.org\/10.1021\/jm801503n","journal-title":"J Med Chem"},{"key":"11619_CR64","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.1021\/jm051205r","volume":"49","author":"Y Sagara","year":"2006","unstructured":"Sagara Y, Sagara T, Uchiyama M et al (2006) Identification of a novel 4-aminomethylpiperidine class of M3 muscarinic receptor antagonists and structural insight into their M3 selectivity. J Med Chem 49:5653\u20135663. https:\/\/doi.org\/10.1021\/jm051205r","journal-title":"J Med Chem"},{"key":"11619_CR65","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.2174\/138161205774370762","volume":"11","author":"J Clader","year":"2005","unstructured":"Clader J, Wang Y (2005) Muscarinic receptor agonists and antagonists in the treatment of alzheimers disease. Curr Pharm Des 11:3353\u20133361. https:\/\/doi.org\/10.2174\/138161205774370762","journal-title":"Curr Pharm Des"},{"key":"11619_CR66","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.bmc.2003.11.005","volume":"12","author":"JW Clader","year":"2004","unstructured":"Clader JW, Billard W, Binch H et al (2004) Muscarinic M2 antagonists: anthranilamide derivatives with exceptional selectivity and in vivo activity. Bioorg Med Chem 12:319\u2013326. https:\/\/doi.org\/10.1016\/j.bmc.2003.11.005","journal-title":"Bioorg Med Chem"},{"key":"11619_CR67","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0024-3205(93)90307-O","volume":"52","author":"HN Doods","year":"1993","unstructured":"Doods HN, Quirion R, Mihm G et al (1993) Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology. Life Sci 52:497\u2013503. https:\/\/doi.org\/10.1016\/0024-3205(93)90307-O","journal-title":"Life Sci"},{"key":"11619_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0014-2999(93)90005-3","volume":"242","author":"H Doods","year":"1993","unstructured":"Doods H, Entzeroth M, Ziegler H et al (1993) Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur J Pharmacol 242:23\u201330. https:\/\/doi.org\/10.1016\/0014-2999(93)90005-3","journal-title":"Eur J Pharmacol"},{"key":"11619_CR69","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/0922-4106(94)90075-2","volume":"268","author":"R Maggio","year":"1994","unstructured":"Maggio R, Barbier P, Bolognesi ML et al (1994) Binding profile of the selective muscarinic receptor antagonist tripitramine. Eur J Pharmacol Mol Pharmacol 268:459\u2013462. https:\/\/doi.org\/10.1016\/0922-4106(94)90075-2","journal-title":"Eur J Pharmacol Mol Pharmacol"},{"key":"11619_CR70","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1021\/acsomega.7b01085","volume":"2","author":"X She","year":"2017","unstructured":"She X, Pegoli A, Mayr J et al (2017) Heterodimerization of dibenzodiazepinone-type muscarinic acetylcholine receptor ligands leads to increased M2 R affinity and selectivity. ACS Omega 2:6741\u20136754. https:\/\/doi.org\/10.1021\/acsomega.7b01085","journal-title":"ACS Omega"},{"key":"11619_CR71","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/acs.jmedchem.6b01892","volume":"60","author":"A Pegoli","year":"2017","unstructured":"Pegoli A, She X, Wifling D et al (2017) Radiolabeled dibenzodiazepinone-type antagonists give evidence of dualsteric binding at the M2 muscarinic acetylcholine receptor. J Med Chem 60:3314\u20133334. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01892","journal-title":"J Med Chem"},{"key":"11619_CR72","doi-asserted-by":"publisher","first-page":"9065","DOI":"10.1021\/jm501173q","volume":"57","author":"A Bonifazi","year":"2014","unstructured":"Bonifazi A, Yano H, Del Bello F et al (2014) Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1). J Med Chem 57:9065\u20139077. https:\/\/doi.org\/10.1021\/jm501173q","journal-title":"J Med Chem"},{"key":"11619_CR73","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1021\/acs.jmedchem.0c00297","volume":"63","author":"O Fischer","year":"2020","unstructured":"Fischer O, Hofmann J, Rampp H et al (2020) Regiospecific introduction of halogens on the 2-aminobiphenyl subunit leading to highly potent and selective M3 muscarinic acetylcholine receptor antagonists and weak inverse agonists. J Med Chem 63:4349\u20134369. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00297","journal-title":"J Med Chem"},{"key":"11619_CR74","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1021\/acs.jmedchem.8b01967","volume":"62","author":"A Pegoli","year":"2019","unstructured":"Pegoli A, Wifling D, Gruber CG et al (2019) Conjugation of short peptides to dibenzodiazepinone-type muscarinic acetylcholine receptor ligands determines M2R selectivity. J Med Chem 62:5358\u20135369. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01967","journal-title":"J Med Chem"},{"key":"11619_CR75","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1016\/j.bmc.2015.01.015","volume":"23","author":"M Keller","year":"2015","unstructured":"Keller M, Tr\u00e4nkle C, She X et al (2015) M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding. Bioorg Med Chem 23:3970\u20133990. https:\/\/doi.org\/10.1016\/j.bmc.2015.01.015","journal-title":"Bioorg Med Chem"},{"key":"11619_CR76","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2174\/0929867013372481","volume":"8","author":"Y Kurogi","year":"2001","unstructured":"Kurogi Y, Guner O (2001) Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr Med Chem 8:1035\u20131055. https:\/\/doi.org\/10.2174\/0929867013372481","journal-title":"Curr Med Chem"},{"key":"11619_CR77","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/rssb.12429","volume":"83","author":"X Luo","year":"2021","unstructured":"Luo X, Dasgupta T, Xie M, Liu RY (2021) Leveraging the fisher randomization test using confidence distributions: inference, combination and fusion learning. J R Stat Soc Ser B Stat Methodol 83:777\u2013797. https:\/\/doi.org\/10.1111\/rssb.12429","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"11619_CR78","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM (2000) The Protein Data Bank. Nucleic Acids Res 28:235\u2013242. https:\/\/doi.org\/10.1093\/nar\/28.1.235","journal-title":"Nucleic Acids Res"},{"key":"11619_CR79","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","volume":"19","author":"GM Morris","year":"1998","unstructured":"Morris GM, Goodsell DS, Halliday RS et al (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639\u20131662. https:\/\/doi.org\/10.1002\/(SICI)1096-987X(19981115)19:14%3C1639::AID-JCC10%3E3.0.CO;2-B","journal-title":"J Comput Chem"},{"key":"11619_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s00706-019-02442-2","author":"RR Ghorpade","year":"2019","unstructured":"Ghorpade RR, Kumar D, Nayak S, Acharya BN (2019) Design and synthesis of muscarinic acetylcholine receptor (mAChR) antagonist: pharmacophore-based screening and structure-based optimization. Monatshefte fur Chemie. https:\/\/doi.org\/10.1007\/s00706-019-02442-2","journal-title":"Monatshefte fur Chemie"},{"key":"11619_CR81","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00706-021-02752-4","volume":"152","author":"BN Acharya","year":"2021","unstructured":"Acharya BN, Ghorpade R, Singh KP et al (2021) Synthesis and muscarinic acetylcholine receptor (mAChR) antagonist activity of substituted piperazine-triazoles. Monatshefte f\u00fcr Chemie - Chem Mon 152:357\u2013366. https:\/\/doi.org\/10.1007\/s00706-021-02752-4","journal-title":"Monatshefte f\u00fcr Chemie - Chem Mon"},{"key":"11619_CR82","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/ACS.JCTC.1C00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, Vald\u00e9s-Tresanco ME, Valiente PA, Moreno E (2021) gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput 17:6281\u20136291. https:\/\/doi.org\/10.1021\/ACS.JCTC.1C00645","journal-title":"J Chem Theory Comput"},{"key":"11619_CR83","doi-asserted-by":"publisher","unstructured":"Boulaamane Y, Saih A, Guendouzi A, Maurady A (2026) Repurposing DrugBank compounds as NAD-dependent deacetylase sirtuin 2 inhibitors via QSAR modelling with gradient boosting algorithms and all-atom molecular simulations. Mol Divers 1\u201324. https:\/\/doi.org\/10.1007\/S11030-026-11504-7","DOI":"10.1007\/S11030-026-11504-7"},{"key":"11619_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/app9214538","author":"TF Vieira","year":"2019","unstructured":"Vieira TF, Sousa SF (2019) Comparing AutoDock and Vina in Ligand\/Decoy discrimination for virtual screening. Appl Sci. https:\/\/doi.org\/10.3390\/app9214538","journal-title":"Appl Sci 2019"},{"key":"11619_CR85","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/CPDD.1361","volume":"13","author":"J Khwarg","year":"2024","unstructured":"Khwarg J, Chung WK, Lee S et al (2024) Evaluation of food effect on the pharmacokinetics of velufenacin, a new muscarinic receptor antagonist, in healthy subjects. Clin Pharmacol drug Dev 13:128\u2013133. https:\/\/doi.org\/10.1002\/CPDD.1361","journal-title":"Clin Pharmacol drug Dev"},{"key":"11619_CR86","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/J.EJPHAR.2018.11.037","volume":"843","author":"MJ Lee","year":"2019","unstructured":"Lee MJ, Moon JH, Lee HK et al (2019) Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland. Eur J Pharmacol 843:240\u2013250. https:\/\/doi.org\/10.1016\/J.EJPHAR.2018.11.037","journal-title":"Eur J Pharmacol"},{"key":"11619_CR87","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1080\/17568919.2024.2400968","volume":"16","author":"S Chahal","year":"2024","unstructured":"Chahal S, Rani P, Singh R et al (2024) Naphthoquinone fused diazepines targeting hyperamylasemia: potential therapeutic agents for diabetes and cancer. Future Med Chem 16:2231\u20132245. https:\/\/doi.org\/10.1080\/17568919.2024.2400968","journal-title":"Future Med Chem"},{"key":"11619_CR88","first-page":"163","volume-title":"Molecular docking: state-of-the-art scoring functions and search algorithms BT\u2014computer-aided and machine learning-driven drug design: from theory to applications","author":"RM de Angelo","year":"2024","unstructured":"de Angelo RM, de Sousa DS, da Silva AP et al (2024) In: Maltarollo VG (ed) Molecular docking: state-of-the-art scoring functions and search algorithms BT\u2014computer-aided and machine learning-driven drug design: from theory to applications. Springer Nature Switzerland, Cham, pp 163\u2013198"},{"key":"11619_CR89","doi-asserted-by":"crossref","unstructured":"Padhi AK, Jane\u017ei\u010d M, Zhang KYJ (2022) Chap. 26\u2014molecular dynamics simulations: principles, methods, and applications in protein conformational dynamics. In: Tripathi T, Dubey VKBT-A in PM and SBM (eds) Academic Press, pp 439\u2013454","DOI":"10.1016\/B978-0-323-90264-9.00026-X"},{"key":"11619_CR90","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449\u2013461. https:\/\/doi.org\/10.1517\/17460441.2015.1032936","journal-title":"Expert Opin Drug Discov"},{"key":"11619_CR91","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang E, Sun H, Wang J et al (2019) End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design. Chem Rev 119:9478\u20139508. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00055","journal-title":"Chem Rev"},{"key":"11619_CR92","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00894-009-0454-9","volume":"15","author":"E Durham","year":"2009","unstructured":"Durham E, Dorr B, Woetzel N et al (2009) Solvent accessible surface area approximations for rapid and accurate protein structure prediction. J Mol Model 15:1093\u20131108. https:\/\/doi.org\/10.1007\/s00894-009-0454-9","journal-title":"J Mol Model"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11619-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:04:02Z","timestamp":1793858642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11619-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":92,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["11619"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11619-x","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}